July 2, 1999
AMERIPATH ANNOUNCES AGREEMENT WITH A. BERNARD ACKERMAN, MD

Riviera Beach, FL, July 2, 1999 - AmeriPath, Inc. (Nasdaq:PATH), an integrated physician group practice committed to providing anatomic pathology services of high quality, has entered into a services agreement effective July 1 with A. Bernard Ackerman, M.D., widely regarded as the preeminent dermatopathologist in the world. Terms of the agreements were not disclosed.

In order to maximize the effectiveness of Dr. Ackerman's affiliation with the Company, AmeriPath has established the "Ackerman Academy of Dermatopathology" and a laboratory for dermatopathology in New York City. The Academy plans to have an accredited dermatopathology fellowship training program with state-of-the-art instrumentation, including a 25-head microscope, and one of the most technologically advanced audiovisual systems available. The diagnostic facility, AmeriPath New York, will operate as a licensed independent outpatient laboratory specializing in dermatopathology. In addition to Dr. Ackerman, these facilities will employ Dr. Joan M. Mones, Dr. Ying Guo, and Dr. Patricia A. Heller, three experienced dermatopathologists.

For the past six years, Dr. Ackerman served as Professor of Dermatology and Pathology, as well as Director of an Institute for Dermatopathology at Jefferson Medical College in Philadelphia. For the previous 20 years, he was Professor of Dermatology and Pathology and Director of Dermatopathology at New York University School of Medicine. In addition to having taught thousands of residents, fellows, and practitioners of dermatology and pathology worldwide, Dr. Ackerman has written more than 35 books about dermatopathology and is the founder and editor of the journal, Dermatopathology: Practical and Conceptual. Two honorary degrees have been bestowed on him from the University of Giessen in Germany in 1998 and from the University of Patras in Greece in 1999. For the past several decades, he has had a very large practice of dermatopathology, characterized particularly by consultations that are sent to him by colleagues in dermatology and pathology who seek his opinion in the diagnosis of difficult cases. In New York City, Dr. Ackerman is affiliated with St. Luke's-Roosevelt Hospital.

"We believe that our affiliation with Dr. Ackerman and the development of these two facilities will propel AmeriPath into the forefront of the practice of dermatopathology worldwide, as well as establish an extensive outpatient practice for our services in a very active New York market," said James C. New, Chairman and CEO of AmeriPath. "We are very proud to announce our association with Dr. Ackerman, and his three colleagues, which should certainly strengthen and enhance AmeriPath's existing group of renowned dermatopathologists. The formation of a teaching academy of this magnitude demonstrates our significant commitment to the advancement of the field of dermatopathology."

"After a six-year hiatus at Jefferson Medical College, I have returned to New York City to co-found what is intended to be the premier teaching center in dermatopathology in the world, namely, the Ackerman Academy of Dermatopathology," commented Dr. Ackerman. "Its purpose is to provide accurate diagnoses with dispatch, to train students of all kinds in dermatopathology, and to advance the perimeter of the field through new observations and novel concepts. The relationship with AmeriPath should enable us to achieve this goal."

AmeriPath, Inc. is the nation's leading physician group practice and laboratory management company focused on providing anatomic pathology services to physicians, hospitals, national clinical laboratories, and managed care organizations. The Company presently operates in eleven states and employs 239 pathologists who provide medical services through outpatient pathology laboratories, hospital inpatient laboratories, and outpatient surgery centers.

................................................................................................................

This release contains certain forward-looking statements regarding AmeriPath, including its operations and prospects. Past performance is not necessarily indicative of future results. In addition, AmeriPath's actual results could differ materially from the results anticipated in these forward-looking statements as a result of uncertainties, including risks relating to demand, pricing, government regulation, payments and reimbursement, changes on reimbursement coding guidelines, dependence upon contracts and pathologists, acquisitions and affiliations, integration of acquired practices, the market for pathology services, competition, and other factors identified in AmeriPath's filings with the Securities and Exchange Commission.